Evidence map›Paper›PMID 38725960›Full record

ArticleOne health (Amsterdam, Netherlands)2024

Susceptibility and transmissibility of SARS-CoV-2 variants in transgenic mice expressing the cat angiotensin-converting enzyme 2 (ACE-2) receptor.

Nereida Jiménez de Oya, Eva Calvo-Pinilla, Patricia Mingo-Casas, Estela Escribano-Romero, Ana-Belén Blázquez, Ana Esteban, Raúl Fernández-González, Eva Pericuesta, Pedro J Sánchez-Cordón, Miguel A Martín-Acebes and 2 more

Abstract read
In one paragraph

Article in One health (Amsterdam, Netherlands), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Nereida Jiménez de OyaDepartamento de Biotecnología, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA-CSIC). Ctra. de La Coruña, km 7, 5, Madrid 28040, Spain.
Eva Calvo-PinillaCentro de Investigación en Sanidad Animal, INIA-CSIC. Carretera Algete-El Casar de Talamanca, Km. 8,1, 28130 Valdeolmos, Madrid, Spain.
Patricia Mingo-CasasDepartamento de Biotecnología, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA-CSIC). Ctra. de La Coruña, km 7, 5, Madrid 28040, Spain.
Estela Escribano-RomeroDepartamento de Biotecnología, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA-CSIC). Ctra. de La Coruña, km 7, 5, Madrid 28040, Spain.
Ana-Belén BlázquezDepartamento de Biotecnología, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA-CSIC). Ctra. de La Coruña, km 7, 5, Madrid 28040, Spain.
Ana EstebanDepartamento de Biotecnología, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA-CSIC). Ctra. de La Coruña, km 7, 5, Madrid 28040, Spain.
Raúl Fernández-GonzálezDepartamento de Reproducción Animal, INIA-CSIC. Av. Puerta de Hierro, 18, Madrid 28040, Spain.
Eva PericuestaDepartamento de Reproducción Animal, INIA-CSIC. Av. Puerta de Hierro, 18, Madrid 28040, Spain.
Pedro J Sánchez-CordónCentro de Investigación en Sanidad Animal, INIA-CSIC. Carretera Algete-El Casar de Talamanca, Km. 8,1, 28130 Valdeolmos, Madrid, Spain.
Miguel A Martín-AcebesDepartamento de Biotecnología, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA-CSIC). Ctra. de La Coruña, km 7, 5, Madrid 28040, Spain.
Alfonso Gutiérrez-AdánDepartamento de Reproducción Animal, INIA-CSIC. Av. Puerta de Hierro, 18, Madrid 28040, Spain.
Juan-Carlos SaizDepartamento de Biotecnología, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA-CSIC). Ctra. de La Coruña, km 7, 5, Madrid 28040, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The emergence of SARS-CoV-2 in 2019 and its rapid spread throughout the world has caused the largest pandemic of our modern era. The zoonotic origin of this pathogen highlights the importance of the One Health concept and the need for a coordinated response to this kind of threats. Since its emergence, the virus has caused >7 million deaths worldwide. However, the animal source for human outbreaks remains unknown. The ability of the virus to jump between hosts is facilitated by the presence of the virus receptor, the highly conserved angiotensin-converting enzyme 2 (ACE2), found in various mammals. Positivity for SARS-CoV-2 has been reported in various species, including domestic animals and livestock, but their potential role in bridging viral transmission to humans is still unknown. Additionally, the virus has evolved over the pandemic, resulting in variants with different impacts on human health. Therefore, suitable animal models are crucial to evaluate the susceptibility of different mammalian species to this pathogen and the adaptability of different variants. In this work, we established a transgenic mouse model that expresses the feline ACE2 protein receptor (cACE2) under the human cytokeratin 18 (K18) gene promoter's control, enabling high expression in epithelial cells, which the virus targets. Using this model, we assessed the susceptibility, pathogenicity, and transmission of SARS-CoV-2 variants. Our results show that the sole expression of the cACE2 receptor in these mice makes them susceptible to SARS-CoV-2 variants from the initial pandemic wave but does not enhance susceptibility to omicron variants. Furthermore, we demonstrated efficient contact transmission of SARS-CoV-2 between transgenic mice that express either the feline or the human ACE2 receptor.

Indexed as

ACE2 receptorAnimal modelsPathogenesisSARS-CoV-2VOCs

Identifiers

PMID38725960
PMCPMC11079394

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.